Humana may also make an acquisition deal and UnitedHealth buys a unit of DaVita; a look at the FDA's expedited review programs; how a billing code discrepancy may have cost taxpayers up to $102 million in Medicare payments to hospitals.
After the CVS—Aetna deal was announced, rumors began swirling that Humana may be next in line for a big deal. Earlier this year, the proposal for Aetna to purchase Humana was blocked by federal judges, and now Humana is making moves that seem to indicate a sale, reported Fierce Healthcare. While the most likely deal would be with Cigna, Humana could also be acquired by Walmart or Walgreens, which would follow in the footsteps of Aetna’s merger across business lines. Meanwhile, UnitedHealth announced it will buy DaVita's primary care unit for $4.9 billion. Reuters reported that DaVita's physician network serves 1.7 million patients every year, but had been a draf on the company's financial performance recently.
A research letter in JAMA analyzed the FDA’s 4 expedited programs to speed up development and review drugs for certain diseases and the outcomes of these drugs. Overall, 60% of new drug approvals from January 2012 to December 2016 were in at least 1 expedited program. The authors compared development times for drugs with priority review or accelerated approval and compared them with drugs not in an expedited program and found that median time from application to approval was almost a full year (0.9 years) shorter for drugs in an expedited program.
For 7 years a Medicare billing code issue may have cost taxpayers up to $102 million in wasteful payments to hospitals. CNBC reported that the issue stemmed from a discrepancy in diagnosis codes—a form of severe protein malnutrition that is rare in the United States had the same code number as less severe forms of malnutritions on one list that is a tool for billing. On another list of coding classification, the rare form had a different code. The number of claims using the code rose from 11,000 to 45,000 a year from 2006 to 2009. The number of claims started to drop after 2009 when the American Hospital Association issued guidance and the discrepancy was fixed in 2015 with the International Classification of Diseases, 10th Revision.
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
President Biden will preview his plan to more than double the size of Medicare’s new drug price negotiation program in the upcoming State of the Union address; Mexicans and Central Americans were most affected by the pandemic in terms of all-cause mortality; two Alabama fertility clinics said they expect to resume in vitro fertilization (IVF) services after a bill was passed to protect doctors.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen